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The recent approval of two protease inhibitors (telaprevir
and boceprevir) and the resultant increase in the sustained
virological response (SVR) rate when either of these drugs is
added to pegylated interferon (PEG-IFN) and ribavirin (RBV)
have led to a flurry of patients with hepatitis C virus (HCV)
infection seeking treatment. Some of these patients had been
diagnosed with HCV for several years and had been hesitant
to receive treatment with PEG-IFN and RBV because of the
low SVR rate, the high frequency of adverse events, and the
need for injections. Others would have been suitable candi-
dates for PEG-IFN and RBV treatment but were fortunate to
have early-stage liver disease and were advised that they could
afford to wait until a more efficacious and/or better tolerated
treatment became available. Still others had gone through one
or more courses of interferon (IFN)-based therapy but had
failed to achieve SVR or could not tolerate the side effects of
PEG-IFN and RBV. This article focuses on patients with an
HCV genotype 1 infection because telaprevir and boceprevir
have not been approved for other HCV genotypes. Patients
with conditions for which telaprevir and boceprevir have not
been approved are also not discussed (Table 1).
Table 2 summarizes the factors that need to be considered in
determining whether a patient should be started on HCV treat-
ment now. Because the new standard of HCV therapy includes
PEG-IFN and RBV, patients with contraindications to these
drugs should not be started on treatment now. A key factor to
the success of triple therapy is the patient’s ability to adhere to
the complex treatment regimen. Telaprevir and boceprevir need
to be administered every 8 hours with a snack, and in the case
of telaprevir, the snack should contain 20 g of fat to facilitate
absorption. Low trough concentrations of telaprevir have been
shown to increase the risk of drug resistance.1 Therefore, treat-
ment should be started only for patients who are motivated and
are able to comply with the treatment regimen.
In comparison with Caucasians, African Americans have signif-
icantly lower SVR rates with PEG-IFN and RBV dual therapy.
The addition of a protease inhibitor to PEG-IFN and RBV
increases the SVR rate2,3 (Fig. 1). Although the SVR rates for Afri-
can Americans are still lower than those for Caucasians, the
improved response to triple therapy has increased the enthusiasm
of physicians and patients alike for pursuing HCV treatment.
In comparison with unfavorable genotypes (CT and TT), a
favorable interleukin-28B (IL-28B) genotype (rs12979860 CC)
is associated with a 2-fold higher rate of SVR to treatment
with PEG-IFN and RBV.4 The addition of telaprevir or boce-
previr to PEG-IFN and RBV has a minimal impact on the SVR
rate of patients with a favorable IL-28B genotype, but there is
a 2- to 3-fold increase in the SVR rate of patients with unfav-
orable IL-28B genotypes5,6 (Fig. 2). Testing for the IL-28B ge-
notype has very little role in determining whether treatment
should be recommended, but in countries with a high preva-
lence of favorable IL-28B genotypes and limited resources, IL-
28B genotyping may help in identifying patients who would
derive the greatest benefit from triple therapy.
Not all patients with chronic HCV will progress to cirrho-
sis; therefore, previous guidelines recommended the initia-
tion of treatment only in patients at risk of progressive liver
disease. An assessment of the liver disease stage has been an
integral part of the pretreatment evaluation. The improved
SVR rate with triple therapy has raised the question whether
HCV treatment should be recommended for all patients,
including those with minimal or no fibrosis. Patients with
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minimal fibrosis are expected to have higher rates of SVR
than those with advanced fibrosis, but some of these patients
may never progress to cirrhosis, and most can afford to wait
for second-generation direct-acting antiviral (DAA) agents or
IFN-free regimens. Patients with cirrhosis have the most
urgent need for treatment, but they are also less likely to
achieve SVR. Patients with bridging fibrosis or cirrhosis had
lower rates of SVR than those with less advanced fibrosis in
the phase 3 trials of boceprevir and telaprevir2,3 (Fig. 3).
Nonetheless, these response rates warrant the recommendation
of triple therapy for patients with cirrhosis as long as some
caveats are noted: the number of patients with cirrhosis
included in the phase 3 trials was small, and all the patients
had compensated cirrhosis with adequate cell counts. Patients
with cirrhosis are more likely to experience adverse events. An
inability to tolerate PEG-IFN and RBV will compromise the
response to triple therapy and increase the risk of antiviral
drug resistance; therefore, caution must be exercised when tri-
ple therapy is being recommended for patients with cirrhosis,








TABLE 2. Factors to Be Considered in Determining Whether the New
Standard of HCV Therapy Should Be Initiated
Host factors: race, age, medical comorbidities, drug interactions, psychoso-
cial circumstances, motivation, ability to adhere to a complex treatment
regimen, and IL-28B genotype
Disease factor: fibrosis stage
Treatment factor: IFN-naive versus IFN-experienced
FIGURE 1. SVR rates (A) for blacks and whites in the ADVANCE trial2 and
(B) for blacks and nonblacks in the SPRINT-2 trial.3 Abbreviations: BPR, boce-
previr and pegylated interferon/ribavirin; BPR48, boceprevir and pegylated
interferon/ribavirin for 48 weeks; PR, pegylated interferon/ribavirin; RGT,
response-guided therapy; SPRINT-2, Serine Protease Inhibitor Therapy 2;
T8PR, telaprevir for 8 weeks and pegylated interferon/ribavirin; T12PR, telap-
revir for 12 weeks and pegylated interferon/ribavirin.
FIGURE 2. SVR rates for patients with IL-28B genotypes CC, CT, and TT in
(A) the ADVANCE trial5 and (B) the SPRINT-2 trial.6 Abbreviations: BPR, boce-
previr and pegylated interferon/ribavirin; BPR48, boceprevir and pegylated
interferon/ribavirin for 48 weeks; PR, pegylated interferon/ribavirin; RGT,
response-guided therapy; SPRINT-2, Serine Protease Inhibitor Therapy 2;
T8PR, telaprevir for 8 weeks and pegylated interferon/ribavirin; T12PR, telap-
revir for 12 weeks and pegylated interferon/ribavirin.
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particularly if treatment is contemplated for patients with low
blood counts or decompensated disease.
The foregoing discussion applies to both IFN-naive
patients and IFN-experienced patients. The addition of boce-
previr or telaprevir to PEG-IFN or RBV increases the SVR
rate for IFN-experienced patients, but the response range is
wide, with very high SVR rates for previous relapsers and
much lower rates for previous null responders7 (Fig. 4).
Retreatment with triple therapy is clearly indicated for relaps-
ers and is worthwhile for most partial responders. Previous
null responders, who are expected to have a 30% chance of
SVR, would be better off waiting for more effective therapies
such as quadruple therapy with PEG-IFN, RBV, and two
DAAs. Patients with cirrhosis and a prior null response may
not be able to wait for newer therapies, but the impulse for
treatment now must be tempered by the sobering fact that
the likelihood of SVR is only 14%, and the possibility of
antiviral drug resistance is >50%.7
The rapid development of DAAs for HCV and the
improved SVR rate with the new standard of HCV therapy
have energized patients and physicians, but the excitement
must be balanced with a careful selection of patients to opti-
mize benefits and to minimize harm.
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FIGURE 3. SVR rates for patients with no, mild, or portal fibrosis (Metavir F0, F1, or F2) or bridging fibrosis and cirrhosis (Metavir F3 or F4) in (A) the ADVANCE
trial2 and (B) the SPRINT-2 trial.3 Abbreviations: BPR, boceprevir and pegylated interferon/ribavirin; BPR48, boceprevir and pegylated interferon/ribavirin for 48
weeks; PR, pegylated interferon/ribavirin; RGT, response-guided therapy; SPRINT-2, Serine Protease Inhibitor Therapy 2; T8PR, telaprevir for 8 weeks and pegylated
interferon/ribavirin; T12PR, telaprevir for 12 weeks and pegylated interferon/ribavirin.
FIGURE 4. SVR rates for patients who experienced relapse or had a partial
or null response to previous therapy in the REALIZE trial according to the pre-
treatment fibrosis stage.7 Abbreviations: PR, pegylated interferon/ribavirin;
T12PR, telaprevir for 12 weeks and pegylated interferon/ribavirin.
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